Document Actions
University of Pittsburgh Cancer Institute
Serum Biomarkers for Colon Cancer
Objective
Develop and validate nuclear matrix proteins as biomarkers for early detection of colon cancer.
Program Description
An integrated multi-disciplinary approach will be used to identify biomarkers for colorectal cancer. The team includes basic cancer researchers and clinicians supported by faculty with expertise in biostatistics/bioinformatics.
Specific Aims
- Characterize, evaluate, and validate a set of unique nuclear matrix proteins (NMPs) which are expressed in colorectal cancer.
- Undertake an extensive Phase 1 and 2 validation study to assess the performance of the NMP biomarker, CC2, for serum-based early detection of colorectal cancer.
- Characterize and evaluate other NMPs, with varying spectrums of expression in pre-malignant (adenomas) and malignant tissue, as potential biomarkers of early disease and/or risk.
Contact Information
Bigbee, William
University Of Pittsburgh Cancer Institute
>
305 Iroquois Bldg.<br>
200 Lothrop St.
>
Pittsburgh, PA 15213<br>
Tel: (412) 967-6534
>
Fax: (412) 967-6576<br>
Email: bigbeewl@msx.upmc.edu
